Approaching Amyloid-Related Imaging Abnormalities (ARIA) in the Emergency Department (ED)



In the ED, ARIA should be considered as a differential diagnosis in patients with Alzheimer's disease (AD) who are receiving anti-amyloid monoclonal antibody (mAb) therapy



What is ARIA?¹

- ARIA are a consequence of amyloid beta (Aβ) buildup in brain blood vessels
- The mobilization of Aβ by mAbs is hypothesized to increase the permeability of blood vessels to fluid or blood products, leading to ARIA

THERE ARE TWO SUBTYPES OF ARIA

ARIA-edema, effusion (ARIA-E): ARIA-hemosiderin, hemorrhage (ARIA-H): • A buildup of fluid on the brain due to damage Hemosiderin deposition in the parenchyma to the blood-brain barrier¹ (microhemorrhages) or leptomeningeal/subpial space (superficial siderosis)^{1,2} • Brain swelling seen as hyperintensities on FLAIR MRI sequences² Bleeds seen as hypointensities on T2* GRE or SWI MRI sequences^{2,3} Hyperintense abnormalities Hypointense abnormalities on FLAIR sequences on T2* GRE sequences Parenchymal Sulcal Superficial vasogenic Cerebral edema effusion microhemorrhages siderosis Rare lobar intracerebral hemorrhage, also termed macrohemorrhages, can also occur⁴

Figures created in Biorender.com. MRI images: data on file.

WHAT ARE COMMON CLINICAL SYMPTOMS OF ARIA?

Patients with symptomatic ARIA may present with varying symptoms, including:¹













Confusion



Dizziness, nausea, or vomiting

Problems with

walking or

balance

Approximately 80% of ARIA cases are asymptomatic and typically detected through routine MRI monitoring^{1,5,6}

DIAGNOSING ARIA IN THE ED²



Medical history:

- ✓ Diagnosis of AD
- Recent or current anti-amyloid treatment Check for medication alert bracelet / medication card

CONSIDER A DIAGNOSIS OF ARIA!





*Figure adapted with permission from Cogswell (2022)⁴; [†]Case courtesy of Balachandran G, Radiopaedia.org, rID-10704⁸; [‡]Case courtesy of Abdrabou A, Radiopaedia.org, rID-22738.⁹

KNOWING IF A PATIENT IS ON AN ANTI-AMYLOID mAb THERAPY IS KEY FOR DIAGNOSIS²

It is essential to gather the appropriate information to support an accurate diagnosis. Inaccurate differential diagnosis of stroke may result in the administration of thrombolytic therapy, which may increase the risk of intracerebral hemorrhage in patients with ARIA¹⁰

GRADING THE SEVERITY OF ARIA⁴



ARIA are graded on the basis of treatment-emergent events. For ARIA-H, this count includes cumulative new microhemorrhages or regions of siderosis compared with the baseline, pretreatment examination.⁴ MRI images 1 to 5 and 7 to 9: data on file.

MRI image 6 adapted with permission from Kate et al. (2018)¹¹ CC BY 4.0: http://creativecommons.org/licenses/by/4.0/

RISK FACTORS FOR ARIA¹

Exposure to anti-amyloid mAb therapy



Anti-amyloid mAb therapy characteristics (e.g., dose, schedule, antibody, treatment duration)

Presence of APOE $\varepsilon 4$ allele

Presence of bleeds before anti-amyloid mAb therapy

Additional risk factors:

- Amount of Aβ plaques in the brain tissue
- Level of Aβ in the cerebral blood vessel walls (CAA)
- Antithrombotic treatment

MANAGING ARIA IN THE ED



In the US, there are currently no evidence-based clinical guidelines for the management of ARIA in the ED⁵

Management of ARIA and stroke are time-sensitive - timely action and appropriate treatment are essential to ensure optimal patient outcomes⁵



Communication about suspected ARIA with patient's neurologist/physician is crucial⁶

Refer to the anti-amyloid mAb prescribing information for guidance. Careful clinical evaluation should be performed prior to continuing anti-amyloid mAb therapy¹²



Scan the QR code for ARIA MRI protocols and additional resources from the American Society of Neuroradiology



Scan the QR code for additional information on ARIA from www.UnderstandingARIA.com

REFERENCES

- Hampel H, et al. Neur odegener Dis Manag. 2024;14(3):51-62. 1.
- Barakos J, et al. AJNR AM J Neuroradiol. 2013;34(10):1958-1965. 2. Hampel H, et al. Brain. 2023;146(11):4414-4424. 3.
- 4.
- Cogswell PM, et al. AJNR Am J Neuroradiol. 2022;43(9):E19–E35. Lo AX, et al. J Am Geriatr Soc. 2024;72(12):3945–3949. 5.
- Cogswell PM, et al. AJNR Am J Neuroradiol. 2025;46(1):24-32. 6.
- Barakos J, et al. J Prev Alzheimers Dis. 2022;9(2):211-220.
- Balachandran G. Radiopaedia.org. https://doi.org/10.53347/rID-10704 8. (Accessed January 2025).
- 9. Abdrabou A. Radiopaedia.org. https://doi.org/10.53347/rID-22738 (Accessed January 2025).
- 10. Reish NJ, et al. N Engl J Med. 2023;388(5):478-479.
- 11 Kate MT et al. Alzheimers Bes Ther. 2018;10(1):112
- 12. Ramanan VK, Day GS. Mol Neurodegener. 2023;18(1):42.

ABBREVIATIONS

Aβ, amyloid beta; AD, Alzheimer's disease; ARIA, amyloid-related imaging abnormalities; ARIA-E, amyloid-related imaging abnormalities – edema, effusion; ARIA-H, amyloid-related imaging abnormalities – hemosiderin, hemorrhage; CAA, cerebral amyloid angiopathy; CT, computerized tomography; DWI, diffusion weighted imaging; ED, emergency department; FLAIR, fluid-attenuated inversion recovery; GRE, gradient recalled echo; mAb, monoclonal antibody; MRI, magnetic resonance imaging; PRES, posterior reversible encephalopathy syndrome; SAH, subarachnoid hemorrhage; SWI, susceptibility weighted imaging; T, Tesla.

This content is intended for healthcare professionals only for educational and informational purposes and does not substitute for sound medical judgment or clinical decision making in the context of medical treatment.

